71 publications
Name | Date | Type | Actions |
---|---|---|---|
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
24/04/2024 | Public releases | |
BALO : Notice of meeting Shareholders are invited to attend the Combined General Meeting to be held on Tuesday May 28, 2024 at 11 a.m. at the Company's registered office, Magny-Vernois 70 200 LURE, in order to deliberate on the following agenda and draft resolutions |
22/04/2024 | Shareholders´s Meeting | |
Bilan semestriel des moyens alloués au contrat de liquidité (2010) - french Au 31 décembre 2010 |
10/01/2011 | Liquidity contract | |
Buyback programs - April 2024 Monthly communication regarding buyback programs |
06/05/2024 | Liquidity contract | |
Buyback programs - March 2024 Monthly communication regarding buyback programs |
04/04/2024 | Description of buyback programs | |
Buyback programs – January 2024 Monthly communication regarding buyback programs |
02/02/2024 | Description of buyback programs | |
CONVOCATION : assemblée d'actionnaires et de porteurs de parts (french) Avis de réunion valant avis de convocation. |
26/04/2011 | Shareholders´s Meeting | |
Descriptif du programme de rachat d’actions propres soumis à Établi en application des dispositions des articles 241-1 et suivant du règlement général de l’Autorité des marchés financiers, le présent descriptif de programme de rachat d’actions propres a pour objet de décrire les finalités et les modalités du programme de rachat d’actions soumis à l’assemblée générale à caractère ordinaire du 20 mai 2011 |
17/05/2011 | Description of buyback programs | |
European launch of new Nsaid Cimalgex® Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs. |
14/06/2011 | Public releases | |
Forcyl®: european launch of new drug Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection. |
29/09/2011 | Public releases |